Back to top

Dianthus Therapeutics (DNTH) Receives a New Rating from Roth MKM

Dianthus Therapeutics received a Buy rating and a $100.00 price target from Roth MKM analyst today. The company’s shares closed yesterday at $37.47...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Dianthus Therapeutics, Inc. (DNTH)